XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Stockholders' Equity
 9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

11. Stockholders’ Equity:

 

We have 2,000,000,000 shares of authorized common stock as of  September 30, 2021 and December 31, 2020. Our common shares have rights to any dividend declared by the board of directors (the "Board"), subject to any preferential or other rights of any outstanding preferred stock, and voting rights to elect all current members of the Board. At September 30, 2021 and December 31, 2020, the closing price of our common stock was $200.27 and $207.59 per share, respectively. 

 

We have 80,000,000 shares of authorized preferred stock, par value $0.001 per share. The preferred shares have preferential rights over the common shares with respect to dividends and net distribution upon liquidation. We did not issue any preferred shares as of September 30, 2021 and December 31, 2020. 

 

On February 17, 2021, April 28, 2021, and July 28, 2021, our Board approved a cash dividend of $0.29 per share of common stock issued and outstanding to the holders of record as of March 15, 2021,  June 15, 2021, and September 15, 2021, respectively. Cash dividends of $141.0 million and $131.8 million were paid during the nine months ended September 30, 2021 and 2020 and recorded as a reduction to retained earnings, respectively. 

 

Share Repurchase Program

 

Since the introduction of share repurchase as a feature of our capital management strategies in 2010, we have authorized repurchases of up to $4,600.0 million of our common stock through our Repurchase Program, inclusive of the $500.0 million authorization approved by our Board on August 17, 2021. We have repurchased shares with an aggregate value of $3,921.2 million. As of September 30, 2021, we had $678.8 million available to repurchase shares through our Repurchase Program. We have no obligation to repurchase stock under this program and intend to use this authorization as a means of offsetting dilution from the issuance of shares under our 2021 Equity Incentive Plan (the "2021 Incentive Plan"), our 2013 Equity Incentive Plan (the "2013 Incentive Plan"), our 2009 Equity Incentive Plan (the "2009 Incentive Plan"), our sharesave plan ("U.K. Sharesave Plan"), and our employee stock purchase plan ("ESPP") while providing flexibility to repurchase additional shares if warranted. This authorization has no expiration date and may be increased, reduced, suspended, or terminated at any time. Shares that are repurchased under our Repurchase Program will be recorded as treasury stock and will be available for future issuance.

 

In December 2020, March 2021, and June 2021, we entered into Accelerated Share Repurchase ("ASR") agreements to repurchase shares of our common stock for an aggregate purchase price of $50.0 million, $125.0 million, and $150.0 million with HSBC Bank USA, N.A and Citibank, N.A. The ASR agreements are each accounted as a treasury stock transaction and forward stock purchase agreement indexed to our common stock. The forward stock purchase agreement is classified as an equity instrument under ASC 815-40, Contracts in Entity's Own Equity ("ASC 815-40") and deemed to have a fair value of zero at the respective effective date. Upon payment of the aggregate purchase price on January 4, 2021, April 1, 2021, and July 1, 2021, we received an aggregate delivery of 192,687, 565,963, and 686,813 shares of our common stock at a price of $207.59, $176.69, and $174.72, respectively. Upon the final settlement of the ASR agreements in February 2021,  May 2021, and September 2021, we received an additional 70,787, 121,965, and 111,429 shares, respectively, as determined by the volume weighted average share price of our common stock during the term of the ASR agreements. The aggregate purchase price was recorded as a reduction to stockholders' equity in our condensed consolidated statements of changes in stockholders' equity for the nine months ended September 30, 2021. These repurchases of 1,749,644 shares for the nine months ended September 30, 2021 resulted in a reduction of outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share ("EPS").

 

During the nine months ended September 30, 2021, we repurchased 2,192,780 shares of common stock with an aggregate value of $400.0 million as part of the Repurchase Program, inclusive of the ASR, at a weighted average price of $182.41 per share. We utilized cash from operations and borrowings from our Credit Facility to fund these repurchases.

 

Treasury Stock

 

As of September 30, 2021, our treasury stock consisted of 382,587,968 shares of common stock, carried at cost. During the nine months ended September 30, 2021, we transferred 790,324 shares of common stock from the treasury shares at a weighted average treasury stock price of $11.54 per share.

 

Earnings Per Share

 

Basic EPS is computed by dividing net income attributable to Verisk by the weighted average number of common shares outstanding during the period. The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding, using the treasury stock method, if the dilutive potential common shares, including vested and nonvested stock options, nonvested restricted stock awards, nonvested restricted stock units, nonvested performance awards consisting of performance share units ("PSU"), and nonvested deferred stock units, had been issued.

 

The following is a presentation of the numerators and denominators of the basic and diluted EPS computations for the three and nine months ended September 30, 2021 and 2020:

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2021

  

2020

  

2021

  

2020

 

Numerator used in basic and diluted EPS:

                

Net income attributable to Verisk

 $201.7  $185.8  $524.3  $536.5 

Denominator:

                

Weighted average number of common shares used in basic EPS

  161,366,544   162,502,191   162,005,382   162,589,473 

Effect of dilutive shares:

                

Potential common shares issuable from stock options and stock-based awards

  1,426,247   3,229,035   1,419,967   2,930,426 

Weighted average number of common shares and dilutive potential common shares used in diluted EPS

  162,792,791   165,731,226   163,425,349   165,519,899 

 

The potential shares of common stock that were excluded from diluted EPS were 740,090 and 40,741 for the three months ended  September 30, 2021 and 2020, and 824,067 and 675,324 for the nine months ended September 30, 2021 and 2020, respectively, because the effect of including these potential shares was anti-dilutive.

 

Accumulated Other Comprehensive Losses

 

The following is a summary of accumulated other comprehensive losses as of September 30, 2021 and December 31, 2020:

 

  

2021

  

2020

 

Foreign currency translation adjustment

 $(347.4) $(292.2)

Pension and postretirement adjustment, net of tax

  (81.2)  (83.5)

Accumulated other comprehensive losses

 $(428.6) $(375.7)

 

The before tax and after tax amounts of other comprehensive income (loss) for the three and nine months ended September 30, 2021 and 2020 are summarized below:

 

  

Before Tax

  

Tax (Expense) Benefit

  

After Tax

 

For the Three Months Ended September 30, 2021

            

Foreign currency translation adjustment

 $(80.4) $—  $(80.4)

Pension and postretirement adjustment before reclassifications

  2.1   (0.6)  1.5 

Amortization of net actuarial loss and prior service benefit reclassified from accumulated other comprehensive losses (1)

  (1.1)  0.3   (0.8)

Pension and postretirement adjustment

  1.0   (0.3)  0.7 

Total other comprehensive loss

 $(79.4) $(0.3) $(79.7)

For the Three Months Ended September 30, 2020

            

Foreign currency translation adjustment

 $115.0  $—  $115.0 

Pension and postretirement adjustment before reclassifications

  3.5   (0.8)  2.7 

Amortization of net actuarial loss and prior service benefit reclassified from accumulated other comprehensive losses (1)

  (1.8)  0.4   (1.4)

Pension and postretirement adjustment

  1.7   (0.4)  1.3 

Total other comprehensive income

 $116.7  $(0.4) $116.3 

 

 

  

Before Tax

  

Tax (Expense) Benefit

  

After Tax

 

For the Nine Months Ended September 30, 2021

            

Foreign currency translation adjustment

 $(55.2) $—  $(55.2)

Pension and postretirement adjustment before reclassifications

  6.2   (1.6)  4.6 

Amortization of net actuarial loss and prior service benefit reclassified from accumulated other comprehensive losses (1)

  (3.1)  0.8   (2.3)

Pension and postretirement adjustment

  3.1   (0.8)  2.3 

Total other comprehensive loss

 $(52.1) $(0.8) $(52.9)

For the Nine Months Ended September 30, 2020

            

Foreign currency translation adjustment

 $(57.7) $—  $(57.7)

Pension and postretirement adjustment before reclassifications

  9.7   (2.3)  7.4 

Amortization of net actuarial loss and prior service benefit reclassified from accumulated other comprehensive losses (1)

  (4.9)  1.2   (3.7)

Pension and postretirement adjustment

  4.8   (1.1)  3.7 

Total other comprehensive loss

 $(52.9) $(1.1) $(54.0)

 

_______________

(1)

These accumulated other comprehensive loss components, before tax, are included under "Cost of revenues" and "Selling, general and administrative" in our accompanying condensed consolidated statements of operations. These components are also included in the computation of net periodic (benefit) cost (see Note 13. Pension and Postretirement Benefits for additional details).